Diana Bilton1, Tacjana Pressler2, Isabelle Fajac3, John Paul Clancy4, Dorota Sands5, Predrag Minic6, Marco Cipolli7, Ivanka Galeva8, Amparo Solé9, Alexandra L Quittner10, Keith Liu11, John P McGinnis11, Gina Eagle11, Renu Gupta11, Michael W Konstan12. 1. Royal Brompton Hospital, London, United Kingdom. 2. Rigshospitalet (Hospital), Copenhagen, Denmark. 3. AP-HP, Université Paris Descartes, Paris, France. 4. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 5. Cystic Fibrosis Department, Institute of Mother and Child, Warsaw, Poland. 6. Institute for Mother and Child Health Care, Department of Pulmonology, Medical School University of Belgrade, Serbia. 7. Azienda Ospedaliera Universitaria Integrata, Verona, Italy. 8. Pediatric Clinic, Infants Department, Alexandrovska University Hospital, Sofia, Bulgaria. 9. Lung Transplant and Cystic Fibrosis Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain. 10. University of Miami, Coral Gables, FL, USA. 11. Insmed Incorporated, Bridgewater, NJ, USA. 12. Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, OH, USA. Electronic address: Michael.Konstan@case.edu.
Abstract
BACKGROUND: Shortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) include poor drug penetration, inactivation by sputum, poor efficiency due to protective biofilm, and short residence in the lung. METHODS: Eligible patients with forced expiratory volume in 1 s (FEV1) ≥25% of predicted value at screening and CF with chronic P. aeruginosa infection were randomly assigned to receive 3 treatment cycles (28 days on, 28 days off) of amikacin liposome inhalation suspension (ALIS, 590 mg QD) or tobramycin inhalation solution (TIS, 300 mg BID). The primary endpoint was noninferiority of ALIS vs TIS in change from baseline to day 168 in FEV1 (per-protocol population). Secondary endpoints included change in respiratory symptoms by Cystic Fibrosis Questionnaire-Revised (CFQ-R). RESULTS: The study was conducted February 2012 to September 2013. ALIS was noninferior to TIS (95% CI, -4.95 to 2.34) for relative change in FEV1 (L) from baseline. The mean increases in CFQ-R score from baseline on the Respiratory Symptoms scale suggested clinically meaningful improvement in both arms at the end of treatment in cycle 1 and in the ALIS arm at the end of treatment in cycles 2 and 3; however, the changes were not statistically significant between the 2 treatment arms. Treatment-emergent adverse events (TEAEs) were reported in most patients (ALIS, 84.5%; TIS, 78.8%). Serious TEAEs occurred in 17.6% and 19.9% of patients, respectively; most were hospitalisations for infective pulmonary exacerbation of CF. CONCLUSIONS: Cyclical dosing of once-daily ALIS was noninferior to cyclical twice-daily TIS in improving lung function. ClinicalTrials.gov Identifier: NCT01315678.
BACKGROUND: Shortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) include poor drug penetration, inactivation by sputum, poor efficiency due to protective biofilm, and short residence in the lung. METHODS: Eligible patients with forced expiratory volume in 1 s (FEV1) ≥25% of predicted value at screening and CF with chronic P. aeruginosa infection were randomly assigned to receive 3 treatment cycles (28 days on, 28 days off) of amikacin liposome inhalation suspension (ALIS, 590 mg QD) or tobramycin inhalation solution (TIS, 300 mg BID). The primary endpoint was noninferiority of ALIS vs TIS in change from baseline to day 168 in FEV1 (per-protocol population). Secondary endpoints included change in respiratory symptoms by Cystic Fibrosis Questionnaire-Revised (CFQ-R). RESULTS: The study was conducted February 2012 to September 2013. ALIS was noninferior to TIS (95% CI, -4.95 to 2.34) for relative change in FEV1 (L) from baseline. The mean increases in CFQ-R score from baseline on the Respiratory Symptoms scale suggested clinically meaningful improvement in both arms at the end of treatment in cycle 1 and in the ALIS arm at the end of treatment in cycles 2 and 3; however, the changes were not statistically significant between the 2 treatment arms. Treatment-emergent adverse events (TEAEs) were reported in most patients (ALIS, 84.5%; TIS, 78.8%). Serious TEAEs occurred in 17.6% and 19.9% of patients, respectively; most were hospitalisations for infective pulmonary exacerbation of CF. CONCLUSIONS: Cyclical dosing of once-daily ALIS was noninferior to cyclical twice-daily TIS in improving lung function. ClinicalTrials.gov Identifier: NCT01315678.
Authors: Peter J Mogayzel; Edward T Naureckas; Karen A Robinson; Gary Mueller; Denis Hadjiliadis; Jeffrey B Hoag; Lisa Lubsch; Leslie Hazle; Kathy Sabadosa; Bruce Marshall Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Alexandra L Quittner; Jie Zhang; Maryna Marynchenko; Pooja A Chopra; James Signorovitch; Yana Yushkina; Kristin A Riekert Journal: Chest Date: 2014-07 Impact factor: 9.410
Authors: Alexandra L Quittner; Gregory S Sawicki; Ann McMullen; Lawrence Rasouliyan; David J Pasta; Ashley Yegin; Michael W Konstan Journal: Qual Life Res Date: 2011-10-14 Impact factor: 4.147
Authors: Alexandra L Quittner; Avani C Modi; Claire Wainwright; Kelly Otto; Jean Kirihara; A Bruce Montgomery Journal: Chest Date: 2009-05-15 Impact factor: 9.410
Authors: Gregory S Sawicki; Clement L Ren; Michael W Konstan; Stefanie J Millar; David J Pasta; Alexandra L Quittner Journal: J Cyst Fibros Date: 2013-01-24 Impact factor: 5.482
Authors: Jeffry Weers; Beth Metzheiser; Glyn Taylor; Simon Warren; Paul Meers; Walter R Perkins Journal: J Aerosol Med Pulm Drug Deliv Date: 2009-06 Impact factor: 2.849
Authors: P Meers; M Neville; V Malinin; A W Scotto; G Sardaryan; R Kurumunda; C Mackinson; G James; S Fisher; W R Perkins Journal: J Antimicrob Chemother Date: 2008-02-27 Impact factor: 5.790
Authors: J P Clancy; L Dupont; M W Konstan; J Billings; S Fustik; C H Goss; J Lymp; P Minic; A L Quittner; R C Rubenstein; K R Young; L Saiman; J L Burns; J R W Govan; B Ramsey; R Gupta Journal: Thorax Date: 2013-06-08 Impact factor: 9.139
Authors: Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli Journal: Antibiotics (Basel) Date: 2021-03-22
Authors: Heidi Wolfmeier; Samuel J T Wardell; Leo T Liu; Reza Falsafi; Annette Draeger; Eduard B Babiychuk; Daniel Pletzer; Robert E W Hancock Journal: Front Microbiol Date: 2022-03-18 Impact factor: 5.640